NASDAQ$DCGO

Docgo Inc · Q3 2025 earnings

Q3 2025 earnings · · After market close · Investor relations

Briefing

DocGo reported Q3 2025, revenue of $70.8M, a net loss of $28.1M.

For Q3 2025, DocGo reported revenue of $70.8M, a net loss of $28.1M. Management discusses operating trends, liquidity, and strategic priorities as disclosed in the quarterly filing.

  • Revenue $70.8M.
  • Net loss $28.1M.
  • DocGo updated clinical, capital, or portfolio priorities in the filing.

Headline financials

Total Revenue

$70.8M

Previous: $139M-48.9%
EPS (adj)

-$0.11

Previous: $0.05-320.0%
GAAP Gross Margin

20.0%

Previous: 33.0%-39.4%
Adjusted Gross Margin

33.0%

Previous: 36.0%-8.3%
Adjusted EBITDA

-$7.2M

Previous: $17.9M-140.2%
Adjusted EBITDA Margin

-10.2%

Previous: 12.9%-179.1%
Cash Flow from Operations

$1.66M

No prior period
Capital Expenditures

-$3.05M

Previous: -$2.94M-3.6%
Net Income

-$27.8M

Previous: $4.55M-710.9%
Operating Income

-$42M

Previous: $10.1M-514.1%
Gross Profit

$14.2M

Previous: $139M-89.8%

Revenue & EPS history

Docgo · Revenue · Quarterly

$70.8M

Q3 2025-48.9%vs Q3 2024
Beat estimate in 11 of 14 quarters(79%)
ActualEstimate

Revenue by segment

Docgo · $187M total across 2 segments · Q3 2023

  • Mobile Health Services
    $139M
  • Transportation Services
    $47.2M

Forward guidance

Management discusses DocGo's outlook, capital deployment, and key risks as disclosed in the earnings materials and periodic report.

Tailwinds

  • DocGo cited progress on strategic priorities in the quarterly filing.
  • Liquidity and balance sheet support continued operations and investment.

Headwinds

  • GAAP profitability remained under pressure in the reported quarter.
  • Macro, competitive, and regulatory factors may affect near-term results.
  • R&D, credit, or project timing can create quarter-to-quarter volatility.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2025

Historical avgQ3 2025

+1.9%

Avg return

Earnings day

+2.0%

Avg return

5 days after

-1.6%

Avg return

30 days after

57%

12 / 21 earnings

Positive

+32.3%

Q2 2021

Best reaction

-40.4%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+2.3%+0.2%-2.6%
Q4 2025+17.7%+4.0%-9.7%
Q3 2025+0.0%-3.6%-15.3%
Q1 2025-40.4%-39.9%-34.3%
Q4 2024-21.2%-22.4%-32.7%
Q3 2024+9.6%+14.0%+11.8%
Q2 2024+18.2%+7.8%+18.2%
Q1 2024-13.5%-11.2%-12.6%
Q4 2023+4.1%+0.3%+3.3%
Q3 2023+1.2%-5.3%-9.3%
Q2 2023+13.9%+12.1%-15.6%
Q1 2023+5.2%+2.4%+11.3%
Q4 2022-1.5%-4.9%-4.7%
Q3 2022-7.7%-5.1%-19.8%
Q2 2022+4.1%+16.9%+11.5%
Q1 2022-0.8%-7.3%+16.7%
Q2 2021+32.3%+48.9%+36.2%
Q4 2021+13.2%+39.2%+29.7%
Q3 2021+4.0%-2.2%-15.9%
Q1 2021-0.4%-0.4%-0.1%
Q4 2020-0.8%-0.5%+0.3%
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro